Repligen Corporation (NASDAQ:RGEN) went up by 5.69% from its latest closing price compared to the recent 1-year high of $159.97. The company’s stock price has collected 2.62% of gains in the last five trading sessions. Press Release reported on 10/01/20 that Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
Is It Worth Investing in Repligen Corporation (NASDAQ :RGEN) Right Now?
Repligen Corporation (NASDAQ:RGEN) scored a price-to-earnings ratio above its average ratio, recording 254.43 x from its present earnings ratio. Plus, the 36-month beta value for RGEN is at 1.01. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Repligen Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $165.86, which is $9.35 above the current price. RGEN currently public float of 48.67M and currently shorts hold a 2.93% ratio of that float. Today, the average trading volume of RGEN was 401.32K shares.
RGEN’s Market Performance
RGEN stocks went up by 2.62% for the week, with a monthly drop of -5.11% and a quarterly performance of 16.98%, while its annual performance rate touched 96.42%. The volatility ratio for the week stands at 2.80% while the volatility levels for the past 30 days are set at 3.42% for Repligen Corporation. The simple moving average for the period of the last 20 days is 7.13% for RGEN stocks with a simple moving average of 32.24% for the last 200 days.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with H.C. Wainwright repeating the rating for RGEN by listing it as a “Buy.” The predicted price for RGEN in the upcoming period, according to H.C. Wainwright is $168 based on the research report published on August 24th of the current year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $151, previously predicting the price at $143. The rating they have provided for RGEN stocks is “Buy” according to the report published on June 30th, 2020.
H.C. Wainwright gave a rating of “Buy” to RGEN, setting the target price at $143 in the report published on May 07th of the current year.
RGEN Trading at 6.09% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.16% of loss for the given period.
Volatility was left at 3.42%, however, over the last 30 days, the volatility rate increased by 2.80%, as shares surge +7.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.59% upper at present.
During the last 5 trading sessions, RGEN rose by +6.37%, which changed the moving average for the period of 200-days by +75.72% in comparison to the 20-day moving average, which settled at $146.65. In addition, Repligen Corporation saw 60.09% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 45,351 shares at the price of $148.20 back on Sep 10. After this action, Hunt Anthony now owns 233,327 shares of Repligen Corporation, valued at $6,721,018 using the latest closing price.
KURIYEL RALF, the Senior VP, R&D of Repligen Corporation, sale 5,000 shares at $153.79 during a trade that took place back on Aug 06, which means that KURIYEL RALF is holding 26,089 shares at $768,950 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- +14.83 for the present operating margin
- +51.15 for the gross margin
The net margin for Repligen Corporation stands at +7.92. The total capital return value is set at 3.93, while invested capital returns managed to touch 2.21. Equity return is now at value 2.90, with 2.20 for asset returns.
Based on Repligen Corporation (RGEN), the company’s capital structure generated 24.85 points at debt to equity in total, while total debt to capital is 19.90. Total debt to assets is 18.81, with long-term debt to equity ratio resting at 24.51. Finally, the long-term debt to capital ratio is 19.63.
Currently, EBITDA for the company is 26.02M with total debt to EBITDA at 3.82. When we switch over and look at the enterprise to sales, we see a ratio of 15.83, with the company’s debt to enterprise value settled at 0.06. The receivables turnover for the company is 6.81 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.28.